Showing results (651-660 of 706) with videos related to

Sort By:
Pageof 71
Cytotherapy|October 26, 2021
Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trialsJoline Ingels, Laurenz De Cock, Rupert L Mayer, et al.
Breast Cancer Research : BCR|October 7, 2024
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2022
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian CancersFelipe Batalini, Doga C Gulhan, Victor Mao, et al.
Nature Structural & Molecular Biology|July 10, 2023
Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike proteinJun Zhang, Weichun Tang, Hailong Gao, et al.
ESMO Open|July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancerI Schlam, D Trapani, S-E Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice GuidelineSaro H Armenian, Christina Lacchetti, Ana Barac, et al.
Breast Cancer Research and Treatment|November 8, 2013
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastasesNancy U Lin, Rachel A Freedman, Naren Ramakrishna, et al.
Biorxiv : the Preprint Server for Biology|May 13, 2022
Structural and functional characteristics of SARS-CoV-2 Omicron subvariant BA.2 spikeJun Zhang, Weichun Tang, Hailong Gao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 18, 2020
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarkerE L Mayer, V Abramson, R Jankowitz, et al.
Journal of the National Cancer Institute|May 19, 2026
Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancerGuilherme Nader-Marta, Yue Zheng, Shoshana M Rosenberg, et al.
Pageof 71